Senti Biosciences Holdings, Inc.
Close on Oct 19, 2026
- Market cap
- $7.06M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 15, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | Before market open | $16.00K | $-0.14 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 27, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | After market close | – | $-0.69 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 28, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 20, 2025 | After market close | – | $-0.67 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | After market close | – | $-6.31 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 21, 2024 | After market close | – | – | – |
Press releases
Announcements Senti Biosciences filed with the SEC
Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial TM Technology Platform
Material agreement · Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Unless we have indicated otherwise or the context requires, the terms the “Company,” “we,” “us,” and “our” refer to Senti Biosciences Holdings, Inc. collectively with its subsidiaries.
Material agreement · Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase
Results of operations · Other events · EX-99.1 to Form 8-K
Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Tim Lu, MD, PhD CEO and Co-Founder 4
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025
Results of operations · EX-99.1 to Form 8-K
Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Senti Bio’s SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights
Results of operations · EX-99 to Form 8-K
Senti Bio Strengthens Leadership Team with Strategic Hires
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Senti Bio Announces Additional $11.5 Million of Financing
New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
SENTI-202 Initial Clinical Data December 2024
Other events · EX-99.1 to Form 8-K
Senti Bio Appoints Fran Schulz to Board of Directors
Material agreement · New financial obligation · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing
Material agreement · New financial obligation · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Other events · EX-99.2 to Form 8-K
Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective
Regulation FD disclosure · EX-99.1 to Form 8-K
Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights
Results of operations · Other events · EX-99.1 to Form 8-K
Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights
Results of operations · EX-99.1 to Form 8-K
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program
Exit or restructuring costs · Other events · EX-99.1 to Form 8-K
Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
Regulation FD disclosure · Other events · EX-99 to Form 8-K
Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates
Results of operations · EX-99.1 to Form 8-K
Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates
Results of operations · EX-99 to Form 8-K
Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Other events · EX-99.1 to Form 8-K
Senti Bio Announces First Quarter 2023 Results and Pipeline Updates
Results of operations · EX-99.1 to Form 8-K
Senti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent Highlights
Results of operations · EX-99.1 to Form 8-K
Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
™ JA N U A R Y 2 0 2 3 | SE N T I B IO SC IE N C E S Engineering the Future of Cell and Gene Therapies 1 January 2023
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
™ JA N U A R Y 2 0 2 3 | SE N T I B IO SC IE N C E S Corporate Presentation 1 January 2023
Other events · EX-99.1 to Form 8-K
Senti Bio Highlights Preclinical Data from Logic-Gated Gene Circuit CAR-NK Cell Therapy SENTI-202
Other events · EX-99.1 to Form 8-K
D E C E M B E R 2 0 2 2 IN V E ST O R E V E N T | SE N T I B IO SC IE N C E S Q&A 34
Other events · EX-99.2 to Form 8-K
D E C E M B E R 2 0 2 2 | SE N T I B IO SC IE N C E S Corporate Presentation December 2022 ™
Other events · EX-99.3 to Form 8-K
Senti Bio Reports Third Quarter Financial Results and Pipeline Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K